{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.5","value":"62.4"},{"comment":"Summary statistics will only be produced if the sample size for the dose group in the respective cycle is 3 or more.","groupId":"OG001","spread":"NA","value":"27.4"}]}],"title":"Cmax"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.95","value":"9.80"},{"comment":"Summary statistics will only be produced if the sample size for the dose group in the respective cycle is 3 or more.","groupId":"OG001","spread":"NA","value":"12.2"}]}],"title":"Cmin"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"The PK parameters for a full PK profile at steady-state were determined in blood using non compartmental methods. The PK parameter: maximum (peak) drug concentration (Cmax) and minimum (trough) drug concentration (Cmin).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received 5 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Everolimus 5 mg/Day"}],"paramType":"MEAN","populationDescription":"The Safety Set consisted of all patients who received any study drug and had at least one postbaseline safety assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 of every cycle (28 days/cycle) throughout the study","title":"Evaluation of Pharmacokinetics (PK) Parameters: Cmax, Cmin","type":"SECONDARY","unitOfMeasure":"ng/mL"}